BrainChip (ASX:BRN) plans to investigate redomiciling from Australia to the US to pursue a listing on a US-based securities exchange, according to a Friday filing with the Australian bourse.
If formally pursued, a scheme of arrangement between the company and its shareholders will be proposed, subject to shareholder and Australian court approval. This timing would position the company for redomiciling by late this year or early 2026, the filing said.
The company would seek to delist its securities from the Australian Securities Exchange as part of the process and maintain existing shareholders' securities listed on the US exchange, equivalent in value to their ASX-listed stock, per the filing.
Shares were down 22% in morning trade Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。